Major Medical Centers Enter into Installation Agreements for Evaluation of BioSig PURE EP™ Systems
February 10 2021 - 10:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it has entered into three new
evaluation agreements for the PURE EP™ System, its novel
electrophysiology (EP) signal acquisition and analysis technology.
New installations of the PURE EP™ System will now follow a
shorter assessment cycle of 90 days based on favorable data from
installation evaluations in 2020. As part of its evaluation
agreements, the Company’s clinical team provides on-site training
and assists with data collection and interpretation, and workflow
customization to optimize the user experience for every physician
and EP lab staff member.
“Since initiating our first clinical study in November 2019, our
team has acquired a wealth of knowledge about the capabilities of
the PURE EP™ System in a broad range of clinical cases,” commented
Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
“Our experience in 2020 has provided the Company meaningful
strategic information that gives us confidence in accelerating our
rollout and reducing the clinical evaluation period to 90 days or
less, beginning with these three major hospitals. With the
recent decline of COVID-19 cases reported and the resulting decline
in hospitalization rates in the past several weeks, our Company is
poised to expand near-term activity on our targeted commercial
plans for 2021.”
New clinical sites due to receive BioSig’s PURE EP™ System
include New York-Presbyterian/Weill Cornell Medical Center,
Michigan Medicine–University Hospital (two centers that account for
two of the largest EP programs in the country), and Houston
Methodist Hospital.
More than 500 patient cases have been conducted using the PURE
EP™ System by 34 physicians in seven clinical sites to
date.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024